Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation

med.stanford.edu · 2,492 words · saved by 1 readers

In an early Stanford Medicine study, CAR-T cell therapy helps some with intractable lymphoma, but those who relapse have few options. Modifying the therapy's molecular target improved response. CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large B-cell lymphoma who haven't experienced improvement with chemotherapy treatments. But if this CAR-T treatment fails, or the cancer returns yet again - as happens in approximately half of people - the prognosis is dire. The median survival time after relapse is about six months. Now, a phase 1 clinical trial at Stanford Medicine has found that a new CAR-T cell therapy that targets a different protein on the surface of the cancer cells significantly improved these patients' outcomes: Over half of 38 people enrolled in the trial - 37 of whom had already relapsed from the original CAR-T therapy - experienced a complete response of their cancer

CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large B-cell lymphoma who haven't experienced improvement with chemotherapy treatments. But if this CAR-T treatment fails, or the cancer returns yet again - as happens in approximately half of people - the prognosis is dire. The median survival time after relapse is about six months. Now, a phase 1 clinical trial at Stanford Medicine has found that a new CAR-T cell therapy that targets a different protein on the surface of the cancer cells sig

Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation

related reading